Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: A report of the CCG-161 study by the Childrens Cancer Study Group

W. A. Bleyer, H. N. Sather, H. J. Nickerson, P. F. Coccia, J. Z. Finklestein, D. R. Miller, P. S. Littman, J. N. Lukens, S. E. Siegel, G. D. Hammond

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

On study CCG-161 of the Childrens Cancer Study Group (CCSG), 631 children with acute lymphoblastic leukemia (ALL) at low risk for relapse were randomized to receive monthly pulses of vincristine-prednisone (VCR-PDN) during maintenance therapy in addition to standard therapy with mercaptopurine (6MP) and methotrexate (MTX), and either cranial irradiation during consolidation or intrathecal (IT) MTX every 3 months during maintenance. All patients received six doses of IT MTX during induction and consolidation. With a minimum follow-up time of 4.25 years, 76.7% receiving VCR-PDN were in continuous complete remission at 5 years, in contrast to 63.9% receiving GMP-MTX alone (P = .002). The difference in relapse-free survival was due primarily to bone marrow relapse (P = .0008), and in boys also to testicular relapse (P = .003). Among the nonirradiated patients, the 5-year disease-free survival (DFS) was 79.4% for patients randomized to the VCR-PDN pulses, in contrast to 61.2% for the patients randomized to receive 6MP-MTX alone (P = .0002). Among the irradiated patients, the DFS was not significantly different. Of the four combinations of maintenance and CNS therapy studied, the highest DFS was achieved with VCR-PDN pulses and maintenance IT MTX.

Original languageEnglish (US)
Pages (from-to)1012-1021
Number of pages10
JournalJournal of Clinical Oncology
Volume9
Issue number6
DOIs
StatePublished - Jan 1 1991

Fingerprint

Vincristine
Prednisone
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methotrexate
Bone Marrow
Recurrence
Disease-Free Survival
Neoplasms
Maintenance
Cranial Irradiation
6-Mercaptopurine
Therapeutics
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia : A report of the CCG-161 study by the Childrens Cancer Study Group. / Bleyer, W. A.; Sather, H. N.; Nickerson, H. J.; Coccia, P. F.; Finklestein, J. Z.; Miller, D. R.; Littman, P. S.; Lukens, J. N.; Siegel, S. E.; Hammond, G. D.

In: Journal of Clinical Oncology, Vol. 9, No. 6, 01.01.1991, p. 1012-1021.

Research output: Contribution to journalArticle

Bleyer, W. A. ; Sather, H. N. ; Nickerson, H. J. ; Coccia, P. F. ; Finklestein, J. Z. ; Miller, D. R. ; Littman, P. S. ; Lukens, J. N. ; Siegel, S. E. ; Hammond, G. D. / Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia : A report of the CCG-161 study by the Childrens Cancer Study Group. In: Journal of Clinical Oncology. 1991 ; Vol. 9, No. 6. pp. 1012-1021.
@article{568b08e2cc3b4319adecbd356ca30d2c,
title = "Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: A report of the CCG-161 study by the Childrens Cancer Study Group",
abstract = "On study CCG-161 of the Childrens Cancer Study Group (CCSG), 631 children with acute lymphoblastic leukemia (ALL) at low risk for relapse were randomized to receive monthly pulses of vincristine-prednisone (VCR-PDN) during maintenance therapy in addition to standard therapy with mercaptopurine (6MP) and methotrexate (MTX), and either cranial irradiation during consolidation or intrathecal (IT) MTX every 3 months during maintenance. All patients received six doses of IT MTX during induction and consolidation. With a minimum follow-up time of 4.25 years, 76.7{\%} receiving VCR-PDN were in continuous complete remission at 5 years, in contrast to 63.9{\%} receiving GMP-MTX alone (P = .002). The difference in relapse-free survival was due primarily to bone marrow relapse (P = .0008), and in boys also to testicular relapse (P = .003). Among the nonirradiated patients, the 5-year disease-free survival (DFS) was 79.4{\%} for patients randomized to the VCR-PDN pulses, in contrast to 61.2{\%} for the patients randomized to receive 6MP-MTX alone (P = .0002). Among the irradiated patients, the DFS was not significantly different. Of the four combinations of maintenance and CNS therapy studied, the highest DFS was achieved with VCR-PDN pulses and maintenance IT MTX.",
author = "Bleyer, {W. A.} and Sather, {H. N.} and Nickerson, {H. J.} and Coccia, {P. F.} and Finklestein, {J. Z.} and Miller, {D. R.} and Littman, {P. S.} and Lukens, {J. N.} and Siegel, {S. E.} and Hammond, {G. D.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1200/JCO.1991.9.6.1012",
language = "English (US)",
volume = "9",
pages = "1012--1021",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia

T2 - A report of the CCG-161 study by the Childrens Cancer Study Group

AU - Bleyer, W. A.

AU - Sather, H. N.

AU - Nickerson, H. J.

AU - Coccia, P. F.

AU - Finklestein, J. Z.

AU - Miller, D. R.

AU - Littman, P. S.

AU - Lukens, J. N.

AU - Siegel, S. E.

AU - Hammond, G. D.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - On study CCG-161 of the Childrens Cancer Study Group (CCSG), 631 children with acute lymphoblastic leukemia (ALL) at low risk for relapse were randomized to receive monthly pulses of vincristine-prednisone (VCR-PDN) during maintenance therapy in addition to standard therapy with mercaptopurine (6MP) and methotrexate (MTX), and either cranial irradiation during consolidation or intrathecal (IT) MTX every 3 months during maintenance. All patients received six doses of IT MTX during induction and consolidation. With a minimum follow-up time of 4.25 years, 76.7% receiving VCR-PDN were in continuous complete remission at 5 years, in contrast to 63.9% receiving GMP-MTX alone (P = .002). The difference in relapse-free survival was due primarily to bone marrow relapse (P = .0008), and in boys also to testicular relapse (P = .003). Among the nonirradiated patients, the 5-year disease-free survival (DFS) was 79.4% for patients randomized to the VCR-PDN pulses, in contrast to 61.2% for the patients randomized to receive 6MP-MTX alone (P = .0002). Among the irradiated patients, the DFS was not significantly different. Of the four combinations of maintenance and CNS therapy studied, the highest DFS was achieved with VCR-PDN pulses and maintenance IT MTX.

AB - On study CCG-161 of the Childrens Cancer Study Group (CCSG), 631 children with acute lymphoblastic leukemia (ALL) at low risk for relapse were randomized to receive monthly pulses of vincristine-prednisone (VCR-PDN) during maintenance therapy in addition to standard therapy with mercaptopurine (6MP) and methotrexate (MTX), and either cranial irradiation during consolidation or intrathecal (IT) MTX every 3 months during maintenance. All patients received six doses of IT MTX during induction and consolidation. With a minimum follow-up time of 4.25 years, 76.7% receiving VCR-PDN were in continuous complete remission at 5 years, in contrast to 63.9% receiving GMP-MTX alone (P = .002). The difference in relapse-free survival was due primarily to bone marrow relapse (P = .0008), and in boys also to testicular relapse (P = .003). Among the nonirradiated patients, the 5-year disease-free survival (DFS) was 79.4% for patients randomized to the VCR-PDN pulses, in contrast to 61.2% for the patients randomized to receive 6MP-MTX alone (P = .0002). Among the irradiated patients, the DFS was not significantly different. Of the four combinations of maintenance and CNS therapy studied, the highest DFS was achieved with VCR-PDN pulses and maintenance IT MTX.

UR - http://www.scopus.com/inward/record.url?scp=0025872488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025872488&partnerID=8YFLogxK

U2 - 10.1200/JCO.1991.9.6.1012

DO - 10.1200/JCO.1991.9.6.1012

M3 - Article

C2 - 2033414

AN - SCOPUS:0025872488

VL - 9

SP - 1012

EP - 1021

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -